IDT Biologika, a contract biologics manufacturer, has agreed to acquire Gallant Custom Laboratories, a vaccine maker based in Ontario, Canada. The transaction is to close August 31, 2015. Gallant Custom Laboratories is authorized by the Canadian Food Inspection Agency (CFIA) to manufacture autogenous viral and bacterial vaccines.

Gallant serves customers throughout Canada, particularly to those who provide vaccines to the Canadian livestock and poultry industry. The company relies on diagnostic laboratory facilities to identify viral and bacterial diseases in pigs, sheep, goats, cattle and poultry, and to subsequently manufacture and supply the appropriate autogenous vaccines corresponding to specific pathogens out of its Cambridge-based manufacturing facilities in Ontario. Gallant presently employs twelve people, and will continue to do business as “Gallant Customs Laboratories, an IDT Biologika company.”

Jackie Gallant, a microbiologist who founded the company 20 years ago, will retain her title as president of Gallant Customs Laboratories and serve in the role of senior executive manager. In addition, she will sit on the IDT Scientific Advisory Board.

IDT Biologika is headquartered in Dessau-Rosslau, Germany, and is a developer and manufacturers of biologics. The company has an additional dedicate animal health vaccine facility in Greifswald – district Riems in Germany. In Denmark, the Netherlands, France, and Spain, IDT’s Animal Health Business Unit operates through its own subsidiaries.

In its recently acquired US manufacturing facility in Rockville, Maryland, IDT Biologika primarily works on vaccine development for clinical Phase I and II projects and provides early-development capabilities for the human vaccine market.

Source: IDT Biologika